Thirty-two month follow-up of successful treatment of choroidal neovascularization from angioid streaks with intravitreal bevacizumab

Ophthalmic Surg Lasers Imaging. 2009 Jan-Feb;40(1):77-9. doi: 10.3928/15428877-20090101-11.

Abstract

A patient presented with subfoveal choroidal neovascularization associated with angioid streaks and was treated with three intravitreal injections of off-label bevacizumab (1.25 mg) in the right eye. Visual acuity improved from 20/70 to 20/20 and remained at this level for 32 months. In certain patients with choroidal neovascularization from angioid streaks, intravitreal bevacizumab may produce normalization of visual acuity and macular anatomy for an extended period of time.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Angioid Streaks / complications
  • Angioid Streaks / diagnosis
  • Angioid Streaks / drug therapy*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Fluorescein Angiography
  • Follow-Up Studies
  • Humans
  • Injections
  • Male
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab